Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) has been assigned a $25.00 price objective by research analysts at Cantor Fitzgerald in a report released on Tuesday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 20.31% from the stock’s previous close. Cantor Fitzgerald also issued estimates for Valeant Pharmaceuticals Intl’s FY2018 earnings at $2.96 EPS.
VRX has been the subject of a number of other research reports. HC Wainwright reaffirmed a “hold” rating and set a $17.00 target price on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, October 4th. Vetr downgraded shares of Valeant Pharmaceuticals Intl from a “strong-buy” rating to a “hold” rating and set a $14.26 target price for the company. in a research note on Friday, October 13th. ValuEngine raised shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating in a research note on Tuesday, December 12th. BMO Capital Markets reaffirmed a “hold” rating and set a $16.00 target price on shares of Valeant Pharmaceuticals Intl in a research note on Monday, October 30th. Finally, TD Securities upgraded shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Tuesday, November 7th. Six analysts have rated the stock with a sell rating, ten have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $17.83.
Valeant Pharmaceuticals Intl (VRX) traded down $0.38 during mid-day trading on Tuesday, reaching $20.78. 10,314,958 shares of the company were exchanged, compared to its average volume of 20,280,000. Valeant Pharmaceuticals Intl has a 12 month low of $8.31 and a 12 month high of $22.81. The company has a market capitalization of $7,240.00, a P/E ratio of 5.33, a P/E/G ratio of 0.59 and a beta of -0.22. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 4.84.
Several institutional investors have recently bought and sold shares of VRX. Legal & General Group Plc increased its holdings in shares of Valeant Pharmaceuticals Intl by 9.2% in the 2nd quarter. Legal & General Group Plc now owns 1,435,670 shares of the specialty pharmaceutical company’s stock worth $23,895,000 after buying an additional 121,032 shares during the last quarter. Blair William & Co. IL boosted its position in Valeant Pharmaceuticals Intl by 58.4% in the 2nd quarter. Blair William & Co. IL now owns 72,866 shares of the specialty pharmaceutical company’s stock valued at $1,261,000 after buying an additional 26,865 shares during the period. BB&T Securities LLC raised its holdings in shares of Valeant Pharmaceuticals Intl by 14.5% in the 2nd quarter. BB&T Securities LLC now owns 40,797 shares of the specialty pharmaceutical company’s stock valued at $705,000 after purchasing an additional 5,165 shares in the last quarter. Marshall Wace North America L.P. bought a new stake in shares of Valeant Pharmaceuticals Intl in the 2nd quarter valued at about $1,597,000. Finally, Tocqueville Asset Management L.P. raised its holdings in shares of Valeant Pharmaceuticals Intl by 3.8% in the 2nd quarter. Tocqueville Asset Management L.P. now owns 21,914 shares of the specialty pharmaceutical company’s stock valued at $379,000 after purchasing an additional 800 shares in the last quarter. Hedge funds and other institutional investors own 49.45% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Cantor Fitzgerald Analysts Give Valeant Pharmaceuticals Intl (VRX) a $25.00 Price Target” was originally reported by American Banking and Market News and is owned by of American Banking and Market News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/29/cantor-fitzgerald-analysts-give-valeant-pharmaceuticals-intl-vrx-a-25-00-price-target.html.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
